Related Experiment Video
Updated: May 10, 2025

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients-A Comprehensive Review
Benoît Henry1, Alain Lefevre Utile2, Stephane Jaureguiberry1,3
1Service des Maladies Infectieuses et Tropicales, APHP, Hôpital Universitaire de Bicêtre, 94275 Le Kremlin-Bicêtre, France.
Abstract:
Intra-abdominal and gastrointestinal mucormycosis are less frequent than rhino-orbito-cerebral and pulmonary mucormycosis, but highly lethal. Their diagnosis remains challenging due to the non-specific clinical presentation. We collected English-language cases of intra-abdominal and gastrointestinal mucormycosis in non-haematological and non-neonatal patients published up to October 2024. This review analysed the epidemiological, clinical, and therapeutic charts of 290 cases. A proportion of 53.4% were reported from India and the USA. The main predisposing conditions were diabetes, solid organ transplant, ICU, and corticosteroid treatment. The most common site was the stomach (53.8%). Gastrointestinal perforation, skin breakdown, and abdominal wall infection were sources of intra-abdominal localisation. The most common symptoms were abdominal pain, vomiting, and gastrointestinal bleeding. The diagnosis relied on histology (93.8%), mycology with microscopy and culture (38.8%), and molecular methods (9.9%). Mortality (52.9%) was lower when treatment was intravenous amphotericin B, combined or not with surgery. Prompt treatment, essential for a favourable outcome, relies on early suspicion and diagnosis. Gastrointestinal and intra-abdominal mucormycosis should also be suspected in patients admitted in ICU with ventilation/nasogastric tube and corticosteroids and those with abdominal trauma or surgery, presenting abdominal distension, pain, and GI bleeding. Mycological diagnosis including direct examination, culture and Mucorales qPCR on tissue should assist with rapid diagnosis and thus treatment.
Insights
Intra-abdominal and gastrointestinal mucormycosis are rare but deadly fungal infections. Early suspicion and diagnosis, particularly in ICU patients, are crucial for effective treatment and improved outcomes.
Area of Science:
- Mycology
- Infectious Diseases
- Gastroenterology
Background:
- Intra-abdominal and gastrointestinal mucormycosis are infrequent but highly lethal infections.
- Diagnosis is challenging due to non-specific clinical presentations.
Purpose of the Study:
- To review epidemiological, clinical, and therapeutic data of intra-abdominal and gastrointestinal mucormycosis.
- To identify key factors influencing patient outcomes.
Main Methods:
- Systematic review of English-language case reports published up to October 2024.
- Analysis of 290 cases in non-hematological, non-neonatal patients.
- Data collection on demographics, predisposing conditions, clinical presentation, diagnosis, and treatment.
Main Results:
- Most cases originated from India and the USA.
- Common predisposing factors include diabetes, solid organ transplant, ICU stay, and corticosteroid use.
- The stomach was the most common site; abdominal pain, vomiting, and GI bleeding were frequent symptoms.
- Histology was the primary diagnostic method, followed by mycology and molecular techniques.
- Mortality was 52.9%, reduced with intravenous amphotericin B and surgery.
Conclusions:
- Early suspicion and prompt diagnosis are vital for favorable outcomes in gastrointestinal and intra-abdominal mucormycosis.
- Consider mucormycosis in ICU patients with risk factors presenting with abdominal symptoms.
- Integrated mycological diagnosis aids rapid identification and treatment initiation.

